Please upgrade your browser.
Our telephone information service (Nurse Hotline) may be accessed directly by calling +1 503 215 7921 or toll-free in the United States of America at 1-866-400-5151, 9 to 4 Pacific, Monday through Friday (excluding federal holidays).
NCCN recently received a research grant from AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. to evaluate the role of tivozanib in the treatment of solid tumors.
Denise Richards: "I was recently given the opportunity to discuss an issue that's very near to my heart with "Living with Cancer" magazine. In the cover story, I share my personal experience with my mother's battle with kidney cancer. I hope you take a look and pass it alongthe first part of prevention is awareness."
Researchers also found those with Lynch syndrome faced a moderately increased risk of developing breast and pancreatic cancers. The finding could lead to earlier detection of a wide range of cancers in sufferers.
A 53-year-old woman presented to our hospital with a non-metastatic 4Â cm renal mass in the right kidney. The patient rejected treatment, but consented to follow-up observation of her condition. The patient underwent a series of computed tomography scans to monitor the progression of the disease.
Studies have shown that patients who are engaged in their care report a better quality of life and are more involved in treatment decisions with their health care team.
"The results demonstrate a novel immunomodulatory effect of entinostat and provide a rationale for the clinical testing of entinostat to enhance cancer immunotherapy," said Roberto Pili, MD, professor of oncology, chief, genitourinary section and co-leader, genitourinary program, department of medicine, Roswell Park Cancer Institute.
This study was performed to investigate whether epigallocatechin-3-gallate (EGCG), the major constituent of green tea, interacted with sunitinib.
We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment.
Chronic kidney disease, even on the milder end of the spectrum, is an independent risk factor for urinary cancers and may therefore be useful for targeting screening, the results of a large observational study suggest.
|Powered by NeonCRM|